These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 1321876)
1. Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62. Lowry PW; Solem S; Watson BN; Koropchak CM; Thackray HM; Kinchington PR; Ruyechan WT; Ling P; Hay J; Arvin AM J Gen Virol; 1992 Apr; 73 ( Pt 4)():811-9. PubMed ID: 1321876 [TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular immunity to varicella-zoster virus glycoprotein gpI and to a non-glycosylated protein, p170, in the strain 2 guinea-pig. Arvin AM; Solem SM; Koropchak CM; Kinney-Thomas E; Paryani SG J Gen Virol; 1987 Sep; 68 ( Pt 9)():2449-54. PubMed ID: 2821181 [TBL] [Abstract][Full Text] [Related]
3. Kinetics and viral protein specificity of the cytotoxic T lymphocyte response in healthy adults immunized with live attenuated varicella vaccine. Sharp M; Terada K; Wilson A; Nader S; Kinchington PE; Ruyechan WT; Hay J; Arvin AM J Infect Dis; 1992 May; 165(5):852-8. PubMed ID: 1314871 [TBL] [Abstract][Full Text] [Related]
4. Varicella-zoster virus glycoprotein gpI/gpIV receptor: expression, complex formation, and antigenicity within the vaccinia virus-T7 RNA polymerase transfection system. Yao Z; Jackson W; Forghani B; Grose C J Virol; 1993 Jan; 67(1):305-14. PubMed ID: 8380078 [TBL] [Abstract][Full Text] [Related]
5. Transcription mapping of glycoprotein I (gpI) and gpIV of varicella-zoster virus and immunological analysis of the gpI produced in cells infected with the recombinant vaccinia virus. Kato T; Kitamura K; Hayakawa Y; Takahashi M; Kojima A; Sato S; Yamanishi K Microbiol Immunol; 1989; 33(4):299-312. PubMed ID: 2549343 [TBL] [Abstract][Full Text] [Related]
7. The synthesis and immunogenicity of varicella-zoster virus glycoprotein E and immediate-early protein (IE62) expressed in recombinant herpes simplex virus-1. Lowry PW; Koropchak CM; Choi CY; Mocarski ES; Kern ER; Kinchington PR; Arvin AM Antiviral Res; 1997 Feb; 33(3):187-200. PubMed ID: 9037375 [TBL] [Abstract][Full Text] [Related]
8. Immune response to vaccinia virus recombinants expressing glycoproteins gE, gB, gH, and gL of Varicella-zoster virus. Kutinová L; Hainz P; Ludvíková V; Maresová L; Nĕmecková S Virology; 2001 Feb; 280(2):211-20. PubMed ID: 11162835 [TBL] [Abstract][Full Text] [Related]
9. Comparison of primary sensitization of naive human T cells to varicella-zoster virus peptides by dendritic cells in vitro with responses elicited in vivo by varicella vaccination. Jenkins DE; Yasukawa LL; Bergen R; Benike C; Engleman EG; Arvin AM J Immunol; 1999 Jan; 162(1):560-7. PubMed ID: 9886433 [TBL] [Abstract][Full Text] [Related]
10. Specific lysis of targets expressing varicella-zoster virus gpI or gpIV by CD4+ human T-cell clones. Huang Z; Vafai A; Lee J; Mahalingam R; Hayward AR J Virol; 1992 May; 66(5):2664-9. PubMed ID: 1348545 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity in mice of varicella-zoster virus glycoprotein I expressed by a vaccinia virus-varicella-zoster virus recombinant. Ludvíková V; Kunke D; Hamsíková E; Kutinová L; Vonka V J Gen Virol; 1991 Jun; 72 ( Pt 6)():1445-9. PubMed ID: 1646285 [TBL] [Abstract][Full Text] [Related]
12. Human T cells recognize multiple epitopes of an immediate early/tegument protein (IE62) and glycoprotein I of varicella zoster virus. Bergen RE; Sharp M; Sanchez A; Judd AK; Arvin AM Viral Immunol; 1991; 4(3):151-66. PubMed ID: 1725699 [TBL] [Abstract][Full Text] [Related]
14. Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis. Kimura H; Wang Y; Pesnicak L; Cohen JI; Hooks JJ; Straus SE; Williams RK J Infect Dis; 1998 Aug; 178(2):310-7. PubMed ID: 9697709 [TBL] [Abstract][Full Text] [Related]
15. The immunogenicity of the Oka/Merck varicella vaccine in relation to infectious varicella-zoster virus and relative viral antigen content. Bergen RE; Diaz PS; Arvin AM J Infect Dis; 1990 Nov; 162(5):1049-54. PubMed ID: 2172393 [TBL] [Abstract][Full Text] [Related]
16. Equivalent recognition of a varicella-zoster virus immediate early protein (IE62) and glycoprotein I by cytotoxic T lymphocytes of either CD4+ or CD8+ phenotype. Arvin AM; Sharp M; Smith S; Koropchak CM; Diaz PS; Kinchington P; Ruyechan W; Hay J J Immunol; 1991 Jan; 146(1):257-64. PubMed ID: 1670603 [TBL] [Abstract][Full Text] [Related]
17. Immunogenicity of a recombinant varicella-zoster virus gE-IE63 fusion protein, a putative vaccine candidate against primary infection and zoster reactivation. Jacquet A; Haumont M; Massaer M; Garcia L; Mazzu P; Daminet V; Grégoire D; Jacobs P; Bollen A Vaccine; 2002 Feb; 20(11-12):1593-602. PubMed ID: 11858867 [TBL] [Abstract][Full Text] [Related]
18. Transcriptional analysis of two simian varicella virus glycoprotein genes which are homologous to varicella-zoster virus gpI (gE) and gpIV (gI). Fletcher TM; Gray WL Virology; 1994 Nov; 205(1):352-9. PubMed ID: 7975231 [TBL] [Abstract][Full Text] [Related]
19. Existence of similar antigenic-sites on varicella-zoster virus gpI and gpIV. Vafai A; Jensen K; Kubo R Virus Res; 1989 Aug; 13(4):319-36. PubMed ID: 2479191 [TBL] [Abstract][Full Text] [Related]
20. The glycoprotein products of varicella-zoster virus gene 14 and their defective accumulation in a vaccine strain (Oka). Kinchington PR; Ling P; Pensiero M; Moss B; Ruyechan WT; Hay J J Virol; 1990 Sep; 64(9):4540-8. PubMed ID: 2166829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]